Cetera Investment Advisers Makes New $208,000 Investment in AdaptHealth Corp. $AHCO

Cetera Investment Advisers acquired a new position in AdaptHealth Corp. (NASDAQ:AHCO) during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 19,187 shares of the company’s stock, valued at approximately $208,000.

Several other hedge funds and other institutional investors have also modified their holdings of the stock. SummerHaven Investment Management LLC increased its holdings in AdaptHealth by 1.7% during the 1st quarter. SummerHaven Investment Management LLC now owns 79,883 shares of the company’s stock valued at $866,000 after purchasing an additional 1,329 shares in the last quarter. Guggenheim Capital LLC lifted its holdings in AdaptHealth by 10.1% during the fourth quarter. Guggenheim Capital LLC now owns 16,613 shares of the company’s stock worth $158,000 after acquiring an additional 1,525 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in AdaptHealth by 3.6% during the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 57,931 shares of the company’s stock worth $552,000 after acquiring an additional 1,999 shares in the last quarter. Oppenheimer Asset Management Inc. lifted its holdings in shares of AdaptHealth by 6.8% in the first quarter. Oppenheimer Asset Management Inc. now owns 32,797 shares of the company’s stock valued at $356,000 after purchasing an additional 2,081 shares in the last quarter. Finally, New York State Teachers Retirement System lifted its holdings in shares of AdaptHealth by 3.3% in the first quarter. New York State Teachers Retirement System now owns 80,455 shares of the company’s stock valued at $872,000 after purchasing an additional 2,600 shares in the last quarter. Institutional investors and hedge funds own 82.67% of the company’s stock.

Insiders Place Their Bets

In other AdaptHealth news, Director David Solomon Williams III sold 8,200 shares of the company’s stock in a transaction dated Friday, August 22nd. The stock was sold at an average price of $9.73, for a total value of $79,786.00. Following the completion of the transaction, the director owned 50,045 shares of the company’s stock, valued at $486,937.85. This represents a 14.08% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 1.55% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

Several analysts recently issued reports on the company. Royal Bank Of Canada dropped their target price on AdaptHealth from $14.00 to $13.00 and set an “outperform” rating on the stock in a report on Thursday, May 8th. Wall Street Zen upgraded AdaptHealth from a “hold” rating to a “buy” rating in a report on Saturday, August 9th. Finally, Truist Financial dropped their target price on AdaptHealth from $14.00 to $13.00 and set a “buy” rating on the stock in a report on Monday, May 12th. Five research analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, the company currently has a consensus rating of “Buy” and an average price target of $13.40.

AdaptHealth Price Performance

AdaptHealth stock opened at $9.61 on Friday. The company has a market capitalization of $1.30 billion, a price-to-earnings ratio of 17.80, a PEG ratio of 1.04 and a beta of 1.58. AdaptHealth Corp. has a 12 month low of $7.11 and a 12 month high of $11.70. The company has a current ratio of 1.06, a quick ratio of 0.82 and a debt-to-equity ratio of 1.14. The stock’s 50 day moving average is $9.22 and its 200-day moving average is $9.25.

AdaptHealth Company Profile

AdaptHealth Corp., together with its subsidiaries, sells home medical equipment (HME), medical supplies, and home and related services in the United States. The company provides sleep therapy equipment, supplies, and related services, such as CPAP and bi-PAP services to individuals suffering from obstructive sleep apnea; medical devices and supplies, including continuous glucose monitors and insulin pumps for the treatment of diabetes; HME to patients discharged from acute care and other facilities; oxygen and related chronic therapy services in the home; and other HME devices and supplies on behalf of chronically ill patients with wound care, urological, incontinence, ostomy, and nutritional supply needs.